Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Orbactiv

Roche Basel Switzerland

AbbVie and Roche’s leukaemia drug venetoclax nears EU market

CHMP grants blood cancer treatment Venclyxto a conditional green light

European regulators give new medicines portal the go-ahead

EMA sets out plans for new online resource for patients, HCPs and academia 

- PMLiVE

Surviving Brexit

How UK biopharma must adapt to a changing landscape

- PMLiVE

AZ withdraws EU filing for ovarian cancer drug cediranib

Maintains cediranib’s value as a combination therapy despite EMA information request

- PMLiVE

EMA’s head of international affairs steps down

Emer Cooke will take up new post at the WHO in November

- PMLiVE

Lilly closes on first approval for sarcoma drug Lartruvo

Orphan drug improved patient survival time by almost 12 months in phase II trial

- PMLiVE

Combatting EU drug shortages

New guidelines to be issued after EMA report

- PMLiVE

Newron back on track for Xadago approval in US

Italian firm is not required to conduct additional trials for its Parkinson’s disease drug

AstraZeneca AZ global R&D corporate HQ

AZ slims down again with sale of antibiotics to Pfizer

Deal does not include biologic anti-infective products from Medimmune unit

- PMLiVE

Patient reporting rises after EU pharmacovigilance reforms

Safety issues detected more quickly with increased patient participation

- PMLiVE

Germany’s IQWIG ‘perplexed’ by EMA’s adaptive pathways plan

Reliance on real-world evidence questioned

- PMLiVE

EMA says adaptive pathways programme still needs refinement

Scheme aims to accelerate patient access to new drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links